Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477999 | 0.97 | EPHX2 (0.45) | HTTEPHX2KMT2ACNR2MEN1 | |
| SCHEMBL3477116 | 0.84 | MAPK1 (0.43) | KMT2ALMNAMAPK1MAPTTDP1 | |
| SCHEMBL3477282 | 0.84 | RAB9A (0.44) | NPC1RAB9ALMNAALDH1A1MAPT | |
| SCHEMBL3477583 | 0.84 | LMNA (0.41) | HTTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3477440 | 0.84 | LMNA (0.43) | KMT2ACNR2LMNAALDH1A1MAPT | |
| SCHEMBL3477114 | 0.84 | MAPT (0.51) | HTTKMT2AMEN1LMNAKDM4E | |
| SCHEMBL3476253 | 0.83 | RAB9A (0.43) | NPC1RAB9ALMNAALDH1A1MAPT | |
| SCHEMBL3476315 | 0.81 | CCKBR (0.39) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL3476757 | 0.81 | NAMPT (0.52) | HTTKMT2ACNR2MEN1LMNA | |
| SCHEMBL3477008 | 0.80 | RAB9A (0.49) | HTTKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, RTF1, POLR1E | HTT 3817/4885EPHX2 2518/4885KMT2A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.